Direct Answer
190 SEC filers are classified under the Standard Industrial Classification code that describes the oncology pharmaceuticals industry, and their latest annual reports show $454.1 billion of combined revenue and a median operating margin of -339.4%. Investors should still evaluate its revenue model, industry-specific KPIs, valuation framework and the risks that can change the group's economics.
Industry Overview
Oncology pharmaceutical companies sell cancer drugs including chemotherapy, targeted therapies and immunotherapies, mostly to hospitals and cancer centers. Treatment duration and combination use drive sales, and patent timelines matter. The first numbers to compare across companies here are sales of key products, treatment duration and market share and pipeline stage.
Key Industry Metrics
- Sales of key products: Revenue of leading cancer drugs. A few products often account for much of results, so their trends matter most.
- Treatment duration and market share: How long patients stay on therapy and the portion of patients using a drug. Longer duration raises sales per patient, and share shows competition.
- Pipeline stage: Where new candidates sit from early trials to approval. Late-stage drugs are closer to launch and offset expiries.
- Patent timeline: Dates when exclusivity ends and biosimilars or generics may enter. Timing shows how long core products are protected.
- Reimbursement: How insurers and government programs pay for drugs, including coverage rules. Payment changes affect net price and access.
Primary Macro Drivers
- Cancer incidence: More cancers are diagnosed as populations age and screening improves, which widens the patients eligible for treatment and supports sales.
- New indications and combinations: Approval for an earlier stage or an additional cancer type expands patients and treatment duration, which raises sales of key products.
- Payer coverage: Insurer coverage decisions determine who receives a costly drug, which sets sales and net price; watch coverage and reimbursement updates.
- Competitive launches: A rival's launch in the same cancer type can take share, so competitor approvals move share and treatment duration.
Major Risks
- Patent expiry and biosimilars: After patent expiry, biosimilars and generics lower prices and take volume; watch patent timeline and exposure of key products.
- Pricing and reimbursement: Government negotiation and rebates lower net price per patient; watch the gap between list and net price and reimbursement news.
- Competition: A new therapy with better results can reduce use of an older one; watch share of key products and competitor trial data.
- Trial failures: A failed study stops a planned launch and its expected sales; watch pipeline stage and readout timing.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Defensive |
| Capital Intensity | Medium |
| Regulatory Intensity | High |
| Industry Maturity | Mature |
| Geographic Importance | U.S. / Global |
Oncology Pharmaceuticals Filers in the SEC Record
190 companies with annual reports in the dataset are classified by the SEC in the Standard Industrial Classification code 2834. Their latest fiscal years end between 2022 and 2026, and together they reported $454.1 billion of revenue. Median revenue growth over the prior year was 11.1%. Median operating margin was -339.4% and median net margin -202.0%. Median total liabilities were 40% of total assets, and 40 of 190 reported a profit in their latest year.
| Company | Revenue | Growth | Operating margin | Net margin | Year |
|---|---|---|---|---|---|
| Johnson & Johnson | $94.2 billion | 6.0% | n/a | 28.5% | FY 2025 |
| Eli Lilly & Co | $65.2 billion | 44.7% | n/a | 31.7% | FY 2025 |
| Pfizer Inc | $62.6 billion | -1.6% | n/a | 12.4% | FY 2025 |
| Abbvie Inc. | $61.2 billion | 8.6% | 24.6% | 6.9% | FY 2025 |
| Bristol Myers Squibb Co | $48.2 billion | -0.2% | n/a | 14.6% | FY 2025 |
| Abbott Laboratories | $44.3 billion | 5.7% | 18.2% | 14.7% | FY 2025 |
| Viatris Inc | $14.3 billion | -3.0% | -18.6% | -24.6% | FY 2025 |
| Vertex Pharmaceuticals Inc / Ma | $12.0 billion | 8.9% | 34.8% | 32.9% | FY 2025 |
The 8 largest of 190 by revenue. Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. A company's SIC code reflects its main business as the SEC records it, so it can differ from how an index provider or analyst classifies the company, and a diversified group appears under only one code.
Where to Go Next
The Oncology Pharmaceuticals guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Ophthalmic Devices
- Oncology Biotechnology
- Ophthalmology Pharmaceuticals
- Obesity & GLP-1 Therapeutics
- Orthopedic Devices
- Neuroscience Biotechnology
- Patient Monitoring
- mRNA Therapeutics
Put it to work
Frequently Asked Questions
What are the main KPIs for the Oncology Pharmaceuticals industry?
Key performance indicators for the Oncology Pharmaceuticals industry include: Sales of key products, Treatment duration and market share, Pipeline stage, Patent timeline, Reimbursement. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Oncology Pharmaceuticals industry?
The Oncology Pharmaceuticals industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions.
What are the biggest risks in the Oncology Pharmaceuticals industry?
The primary risks for Oncology Pharmaceuticals companies include: Patent expiry and biosimilars, Pricing and reimbursement, Competition, Trial failures. Investors should assess each company's exposure to these factors and its track record of navigating them.